Nitazoxanide: A first-in-class broad-spectrum antiviral agent

Antiviral Research

Volumn 110, Issue , 2014, Pages 94-103

  Rossignol, Jean François ^a,b  

^a Romark Institute for Medical Research   (United States)

^b Romark Laboratories   (United States)

Author keywords

Antiviral therapy; Broad spectrum; Influenza; Nitazoxanide; Thiazolides

Indexed keywords

NITAZOXANIDE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; THIAZOLIDINE DERIVATIVE; TIZOXANIDE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; BRONCHITIS; CELL CULTURE; CHILL; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONAVIRUS; COUGHING; DENGUE; DENGUE VIRUS; DIARRHEA; DNA VIRUS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MARKETING; DRUG POTENTIATION; DRUG STRUCTURE; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN ROTAVIRUS; INFLUENZA A; INFLUENZA B; INSOMNIA; JAPANESE ENCEPHALITIS VIRUS; MUSCULOSKELETAL STIFFNESS; NAUSEA; NIGHT SWEAT; NOROVIRUS; NOSE OBSTRUCTION; OROPHARYNX PAIN; OTALGIA; OTITIS MEDIA; PARAINFLUENZA VIRUS; PERSONAL EXPERIENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; ROTAVIRUS; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRAL GASTROENTERITIS; VIRAL RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VIRUS SHEDDING; VOMITING; WHEEZING; XEROSTOMIA; YELLOW FEVER FLAVIVIRUS; DNA VIRUS INFECTIONS; DRUG EFFECTS; DRUG REPOSITIONING; INFLUENZA, HUMAN;

ANTIPARASITIC AGENTS; ANTIVIRAL AGENTS; DNA VIRUS INFECTIONS; DRUG REPOSITIONING; HUMANS; INFLUENZA, HUMAN; THIAZOLES; VIRUS REPLICATION;

EID: 84906669535     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.07.014     Document Type: Review

References (62)

1. B. Amadi, M. Mwiya, J. Musuku, A. Watuka, S. Sianongo, A. Ayoub, and P. Kelly Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial Lancet 360 2002 1375 1380 (Pubitemid 35341302)
2. 2+ stores Virology 462-463 2014 135 148
3. L.V. Ashton, R.L. Callan, S. Rao, and G.A. Landoldt In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide Vet. Med. Int. 2010 2010 (article ID 891010)
4. A. Baishanbo, G. Gargala, C. Duclos, A. François, J.F. Rossignol, J.J. Ballet, and L. Favennec Efficacy of nitazoxanide and paromomycin on biliary tract cryptosporidiosis in an immunosuppressed gerbil model J. Antimicrob. Chemother. 57 2006 353 355 (Pubitemid 43160183)
5. Belardo, G., La Frazia, S., Cenciarelli, O., Carta, S., Rossignol, J.F., Santoro, M.G., 2011. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors. Poster presented at: 49th Infectious Disease Society of America Annual Meeting, Oct 20-23, 2011, Boston, Massachusetts. https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html.
6. B.L. Blagburn, K.L. Drain, T.M. Land, R.G. Kinard, P.H. Moore, D.S. Lindsay, D.A. Patrick, D.W. Boykin, and R.R. Tidwell Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model Antimicrob. Agents Chemother. 42 1998 2877 2882 (Pubitemid 28501219)
7. J. Broekhuysen, A. Stockis, R.L. Lins, J. De Graeve, and J.F. Rossignol Nitazoxanide: pharmacokinetics and metabolism in man Int. J. Clin. Pharmacol. Ther. 38 2000 387 394 (Pubitemid 30650157)
8. R. Cavier, and J.F. Rossignol Etude de diverses associations d'anthelminthiques chez la souris Rev. Méd. Vét. 133 1982 779 783 (Pubitemid 13195827)
9. M. Clerici, D. Trabattoni, M. Pacei, M. Biasin, and J.F. Rossignol The anti-infective nitazoxanide shows strong immuno-modulating effects [abstract] J. Immunol. 186 155 2011 21
10. L.P. De Carvalho, G. Lin, X. Jiang, and C. Nathan Nitazoxanide kills replicating and non-replicating Mycobacterium tuberculosis and evades resistance J. Med. Chem. 52 2009 5789 5792
11. L.P. De Carvalho, C.M. Darby, K.Y. Rhee, and C. Nathan Nitazoxanide disrupts membrane potential and intra-bacterial pH homeostasis of Mycobacterium tuberculosis ACS Med. Chem. Lett. 2 2011 849 854
12. Y. Debing, D. Jochmans, and J. Neyts Intervention strategies for emerging viruses: use of antivirals Curr. Opin. Virol. 3 2013 217 224
13. M.S. Diarmond, and M. Farzan The broad-spectrum antiviral functions of IFIT and IFITM proteins Nat. Rev. Immunol. 13 2013 46 57
14. L. Dubreuil, I. Houcke, Y. Mouton, and J.F. Rossignol In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms Antimicrob. Agents Chemother. 40 1996 2266 2270 (Pubitemid 26328028)
15. M. Elazar, M. Liu, S.A. McKenna, P. Liu, E.A. Gehrig, J.D. Puglisi, J.F. Rossignol, and J.S. Glenn The anti-hepatic C agent nitazoxanide induces phosphorylation of eIF2-alpha via PKR activation Gastroenterology 137 2009 1827 1835
16. J. Euzeby, T.S. Prom, and J.F. Rossignol Experimentation des propriétés anthelminthiques de la nitazoxanide chez le chien, le chat et les ovins Rev. Méd. Vét. 131 1980 687 696 (Pubitemid 11161770)
17. S.M. Finegold, D. Molitoris, and M.L. Vaisanen Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora Antimicrob. Agents Chemother. 53 2009 281 286
18. J. Freeman, S.D. Baines, S.L. Todhunter, G.S. Huscroft, and M.H. Wilcox Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole J. Antimicrob. Chemother. 66 2011 1407 1408
19. G. Gargala, L. Le Goff, J.J. Ballet, L. Favennec, A.V. Stachulski, and J.F. Rossignol Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro-group-independent efficacy against Cryptosporidium parvum Antimicrob. Agents Chemother. 54 2010 1315 1318
20. G. Gargala, A. François, L. Favennec, and J.F. Rossignol Activity of halogeno-thiazolides against Cryptosporidium parvum in experimentally infected immunosuppressed gerbils (Meriones unguiculatus) Antimicrob. Agents Chemother. 57 2013 2821 2823
21. Gubareva, L.V., Marjuki, H., Mishin, V.P., Sleeman, K., Tamura, D., Chesnokov, A., De La Cruz, J., Villaneuva, J., Davis, T., 2014. Susceptibility of avian influenza A(H7N9) viruses to FDA approved and investigational antiviral drugs. Programme & Abstract Book, Influenza and Other Respiratory Virus Infections: Advances in Clinical Management. Third ISIRV-Antiviral Group Conference. Abstract P57, 83.
22. J. Haffizulla, A. Hartman, M. Hoppers, H. Resnick, S. Samudrala, C. Ginocchio, M. Bardin, and J.F. Rossignol A randomized, double-blind, placebo controlled clinical trial of nitazoxanide in adults and adolescents with acute uncomplicated influenza Lancet Infect. Dis. 14 2014 609 618
23. D.W. Hecht, M.A. Galang, S.P. Sambol, J.R. Osmolski, S. Johnson, and D.N. Gerding In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004 Antimicrob. Agents Chemother. 51 2007 2716 2719 (Pubitemid 47206204)
24. P.S. Hoffman, G. Sisson, M.A. Croxen, K. Welch, W.D. Harman, N. Cremades, and M.G. Morash Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni Antimicrob. Agents Chemother. 51 2007 868 876 (Pubitemid 46355269)
25. S.S. Kaufman, K.Y. Green, and B.E. Korba Treatment of norovirus infections: moving antivirals from the bench to the bedside Antiviral Res. 105 2014 80 91
26. B.E. Korba, A.B. Mueller, K. Farrar, K. Gaye, S. Mukerjee, M.S. Ayers, and J.F. Rossignol Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication Antiviral Res. 77 2008 56 63
27. B.E. Korba, M. Elazar, P. Lui, J.F. Rossignol, and J.S. Glenn Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines Antimicrob. Agents Chemother. 52 2008 4069 4071
28. S. La Frazia, A. Ciucci, F. Arnoldi, M. Coira, P. Gianferreti, M. Angelini, G. Belardo, O. Burrone, J.F. Rossignol, and G.M. Santoro Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis inhibiting viroplasm formation J. Virol. 83 2013 11096 11101
29. X. Li, P. Brasseur, P. Agnamey, D. Lemeteil, L. Favennec, J.J. Ballet, and J.F. Rossignol Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model Folia Parasitol. (Praha) 50 2003 19 22 (Pubitemid 36521952)
30. C.S. McVay, and R.D. Rolfe In vitro and in vivo activities of nitazoxanide against Clostridium difficile Antimicrob. Agents Chemother. 44 2000 2254 2258 (Pubitemid 30650864)
31. F. Mégraud, A. Occhialini, and J.F. Rossignol Nitazoxanide, a potential drug to eradicate Helicobacter pylori with no cross-resistance to metronidazole Antimicrob. Agents Chemother. 42 1998 2836 2840 (Pubitemid 28501212)
32. Meneses, M.D.S., Duarte, R.S., Migowski, E.R., Ferreira, D.F., 2013. In vitro study on the effects of nitazoxanide on the replication of dengue virus and yellow fever virus. Poster Presented at the 28th International Conference on Antiviral Research (ICAR). Abstract #157, 101.
33. D.M. Musher, N. Logan, R.J. Hamill, H.L. DuPont, A. Lentnek, A. Gupta, and J.F. Rossignol Nitazoxanide in the treatment of Clostridium difficile colitis Clin. Infect. Dis. 43 2006 421 427 (Pubitemid 44157148)
34. D.M. Musher, N. Logan, A.M. Bressler, D.P. Johnson, and J.F. Rossignol Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study Clin. Infect. Dis. 48 2009 41 46
35. J.J. Ortiz, A. Ayoub, G. Gargala, N.L. Chegne, and L. Favennec Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru Aliment. Pharmacol. Ther. 15 2001 1409 1415 (Pubitemid 32835549)
36. G.A. Pankuch, and P.C. Appelbaum Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species Antimicrob. Agents Chemother. 50 2006 112 117
37. Romark Laboratories, L.C. Alinia® (nitazoxanide) prescribing information. 2007.
38. J.F. Rossignol, and R. Cavier Synthesis and antiparasitic activity of 2-benzamido nitrothiazoles Chem. Abstr. 83 1975 28216n
39. J.F. Rossignol, and Y. El-Gohary Nitazoxanide in treatment of viral gastroenteritis: a randomized, double-blind, placebo-controlled clinical trial Aliment. Pharmacol. Ther. 24 2006 1423 1430 (Pubitemid 44657118)
40. J.F. Rossignol, and E.B. Keeffe Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C Future Microbiol. 3 2008 539 545
41. J.F. Rossignol, and H. Maisonneuve Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana Am. J. Trop. Med. Hyg. 33 1984 511 512 (Pubitemid 14075656)
42. Rossignol, J.F., Santoro M.G., 2014. Activity of thiazolides against other respiratory viruses than influenza. Programme & Abstract Book, Influenza and Other Respiratory Virus Infections: Advances in Clinical Management. Third ISIRV-Antiviral Group Conference. Abstract P54, 81.
43. J.F. Rossignol, and A. Stachulski Synthesis and antibacterial activities of tizoxanide and its o-aryl glucuronide J. Chem. Res. 1999 44 45
44. J.F. Rossignol, A. Ayoub, and M.S. Ayers Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized double-blind placebo-controlled study of nitazoxanide J. Infect. Dis. 184 2001 103 106 (Pubitemid 32568508)
45. J.F. Rossignol, M. Abu-Zekry, H. Abeer, and M.G. Santoro Effect of nitazoxanide in treating severe rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial Lancet 368 2006 124 129 (Pubitemid 43994153)
46. J.F. Rossignol, S.M. Kabil, Y. El-Gohary, A. Elfert, and E.B. Keeffe Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype-4 Aliment. Pharmacol. Ther. 28 2008 574 580
47. J.F. Rossignol, S. La Frazia, L. Chiappa, A. Ciucci, and M.G. Santoro Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level J. Biol. Chem. 284 2009 29798 29808
48. J.F. Rossignol, A. Elfert, Y. El-Gohary, and E.B. Keefe Improved virologic response in chronic hepatitis C genotype-4. Patients given nitazoxanide, peginterferon, and ribavirin Gastroenterology 136 2009 856 862
49. J.F. Rossignol, A. Elfert, and E.B. Keeffe Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide J. Clin. Gastroenterol. 44 2010 504 509
50. J.F. Rossignol, N. Lopez-Chegne, L.M. Julcamoro, M.E. Carrion, and M.C. Bardin Nitazoxanide for the empiric treatment of pediatric infectious diarrhea Trans. R. Trop. Med. Hyg. 106 2012 167 173
51. M.L. Shaw The host interactome of influenza virus presents new potential targets for antiviral drugs Rev. Med. Virol. 21 2011 358 369
52. X. Shi, J. Wei, X. Deng, S. Li, Y. Qiu, D. Shao, B. Li, K. Zhang, F. Xue, X. Wang, and Z. Ma Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model Virol. J. 11 2014 10 10.1186/1743-422X-11-109
53. D.M. Siddiq, H.L. Koo, J.A. Adachi, and G.M. Viola Norovirus gastroenteritis successfully treated with nitazoxanide J. Infect. 63 2011 394 397
54. K. Sleeman, V.P. Mishin, Z. Guo, R.J. Garten, A. Balish, A.M. Fry, J. Villanueva, J. Stevens, and V. Gubavera Antiviral susceptibility of variant influenza A (H3N2)v viruses isolated in the United States during 2011-2013 Antimicrob. Agents Chemother. 58 2014 2045 2051
55. A.V. Stachulski, C. Pidathala, E.C. Row, R. Sharma, N.G. Berry, M. Iqbal, J. Bentley, S.A. Allman, I.G. Edwards, A. Helm, J. Hellier, B.E. Korba, J.E. Semple, and J.F. Rossignol Thiazolides as novel antiviral agents: I. Inhibition of hepatitis B virus J. Med. Chem. 54 2011 4119 4132
56. A.V. Stachulski, C. Pidathala, E.C. Row, R. Sharma, N.G. Berry, M. Iqbal, J. Bentley, S.A. Allman, I.G. Edwards, A. Helm, J. Hellier, B.E. Korba, J.E. Semple, and J.F. Rossignol Thiazolides as novel antiviral agents: II. Inhibition of the hepatitis C virus J. Med. Chem. 54 2011 8670 8680
57. X. Tan, L. Hu, L.J. Luquette 3rd, G. Gao, Y. Liu, H. Qu, R. Xi, Z.J. Lu, P.J. Park, and J. Elledge Systematic identification of synergistic drug pairs targeting HIV Nat. Biotechnol. 30 2012 1125 1130
58. J. Taubel, U. Lorch, J.F. Rossignol, J. Ferber, and A. Camm Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study J. Clin. Pharmacol. 2014 10.1002/jcph.300 (Epub ahead of print)
59. C.G. Teran, C.N. Teran-Escalera, and P. Villarroel Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind controlled trial in Bolivian children Int. J. Infect. Dis. 13 2009 518 523
60. C.M. Theodos, J.K. Griffiths, J. D'Onfro, A. Fairfield, and S. Tzipori Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models Antimicrob. Agents Chemother. 42 1998 1959 1965 (Pubitemid 28363076)
61. C. Yon, P. Viswanathan, J.F. Rossignol, and B.E. Korba Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells Antiviral Res. 91 2011 233 240
62. Y. Zhou, and G. Simmons Development of novel entry inhibitors targeting emerging viruses Expert Rev. Anti. Infect. Ther. 10 2012 1129 1138